[go: up one dir, main page]

IL132537A0 - Truncated vegf-related proteins - Google Patents

Truncated vegf-related proteins

Info

Publication number
IL132537A0
IL132537A0 IL13253798A IL13253798A IL132537A0 IL 132537 A0 IL132537 A0 IL 132537A0 IL 13253798 A IL13253798 A IL 13253798A IL 13253798 A IL13253798 A IL 13253798A IL 132537 A0 IL132537 A0 IL 132537A0
Authority
IL
Israel
Prior art keywords
related proteins
truncated vegf
vegf
truncated
proteins
Prior art date
Application number
IL13253798A
Original Assignee
Collateral Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collateral Therapeutics filed Critical Collateral Therapeutics
Publication of IL132537A0 publication Critical patent/IL132537A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13253798A 1997-04-25 1998-04-20 Truncated vegf-related proteins IL132537A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298497A 1997-04-25 1997-04-25
PCT/US1998/007801 WO1998049300A2 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Publications (1)

Publication Number Publication Date
IL132537A0 true IL132537A0 (en) 2001-03-19

Family

ID=25288752

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13253798A IL132537A0 (en) 1997-04-25 1998-04-20 Truncated vegf-related proteins

Country Status (10)

Country Link
EP (1) EP0977854A2 (en)
JP (1) JP2001524828A (en)
KR (1) KR20010020259A (en)
CN (2) CN1680442A (en)
AU (1) AU7250298A (en)
CA (1) CA2287538A1 (en)
EA (1) EA199900861A1 (en)
IL (1) IL132537A0 (en)
NZ (2) NZ514872A (en)
WO (1) WO1998049300A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
DK0751992T3 (en) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
JPH11514976A (en) 1995-09-08 1999-12-21 ジェネンテク・インコーポレイテッド VEGF-related proteins
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CN1299407A (en) * 1998-03-13 2001-06-13 人体基因组科学有限公司 Vascular endothelial growth factor 2
DE19813774A1 (en) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapox virus-encoded vascular endothelial cell growth factor (PPV-VEGF)
EP1121143A2 (en) * 1998-03-27 2001-08-08 Dorothea J. Eicher Vegf and vegf-c as infant formula supplements
CA2340598A1 (en) 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
AU768330B2 (en) * 1998-10-26 2003-12-11 Vegenics Limited Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
EP1568375A1 (en) * 1998-10-26 2005-08-31 Ludwig Institute For Cancer Research Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
DE69939484D1 (en) 1998-10-28 2008-10-16 Cornell Res Foundation Inc METHODS FOR REGULATING ANGIOGENESIS AND VASCULAR INTEGRITY BY TRK RECEPTOR LIGANDS BDNF, NT-3 AND NT-4
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
EP1604024A4 (en) * 2000-04-06 2008-04-23 Wayne P Franco Methods of using growth factors for treating heart disease
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
NZ518077A (en) 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US7405278B2 (en) 2000-08-10 2008-07-29 Masabumi Shibuya Chimeric human-type vascular endothelial cell growth factor
EP1191104A1 (en) * 2000-09-26 2002-03-27 Introgene B.V. Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
EP1341914A2 (en) 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation of angiogenesis with zinc finger proteins
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2005505510A (en) 2001-06-20 2005-02-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Stimulation of angiogenesis by VEGF-B
PT1438049E (en) 2001-10-15 2007-02-28 Janssen Pharmaceutica Nv Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20120141424A1 (en) * 2009-01-07 2012-06-07 Vegenics Pty Limited Materials and Methods for the Treatment of Hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1242149B (en) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
EP1321526A3 (en) * 1992-11-18 2003-07-02 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
CA2214439C (en) * 1995-03-02 2002-12-17 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
CA2224002A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Also Published As

Publication number Publication date
AU7250298A (en) 1998-11-24
EP0977854A2 (en) 2000-02-09
JP2001524828A (en) 2001-12-04
WO1998049300A2 (en) 1998-11-05
NZ500530A (en) 2001-12-21
NZ514872A (en) 2005-01-28
EA199900861A1 (en) 2000-06-26
KR20010020259A (en) 2001-03-15
CN1260835A (en) 2000-07-19
WO1998049300A3 (en) 1999-03-11
CN1680442A (en) 2005-10-12
CA2287538A1 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
IL132537A0 (en) Truncated vegf-related proteins
GB9718609D0 (en) Fusion protein
PT1090128E (en) Modified vitamin-k-dependent polypeptides
GB9724783D0 (en) Novel polypeptides
ZA9710338B (en) Proteins
IL133582A0 (en) Mammalian neuro-growth factor like protein
GB9719879D0 (en) Protein
GB9703681D0 (en) Protein complemention
GB9718110D0 (en) Peptides
GB9701710D0 (en) Mammalian protein
ZA984322B (en) Sucrose-binding proteins
GB9700154D0 (en) Peptides
GB9720784D0 (en) Protein
EP1037898A4 (en) Secreted proteins
AU2002300742A1 (en) Truncated Vegf-related Proteins
GB9722727D0 (en) Proteins
GB9722003D0 (en) Proteins
GB9707822D0 (en) Proteins
GB9707499D0 (en) Proteins
GB9703104D0 (en) Proteins
GB9700121D0 (en) Proteins
ZA971900B (en) Modified proteins
GB9706119D0 (en) Novel protein
GB9703850D0 (en) Novel protein
GB9704252D0 (en) Novel protein